Tenax Therapeutics Inc Dossier - Source-backed chat

Tenax Therapeutics Inc

TENXNASDAQ

SectorHealth Care

IndustryPharmaceuticals

Beta (adjusted)0.95

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.89Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $70.7M

Enterprise Value −$47.3M

Shares Outstanding 37.4M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Tenax Therapeutics is a high-conviction, late-stage clinical biopharmaceutical company focused on developing oral levosimendan (TNX-103) for Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF). This condition represents a massive, multi-billion dollar market with no currently approved FDA therapies. With the pivotal Phase 3 LEVEL study fully randomized and topline data expected in Q3 2026, the company is on the cusp of a major clinical catalyst. Backed by a robust cash position of $118.8 million (runway through Q1 2028) and a newly strengthened executive team, Tenax is well-positioned to transition from a development-stage entity to a commercial-stage leader or prime acquisition target.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets10 analysts · as of 18 Aug 2026

Low · most bearish analyst$4.00

Mean target$11.70

High · most bullish analyst$36.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The LEVEL study fails to meet its primary endpoint of 6MWD or shows safety concerns (e.g., adverse cardiovascular events), severely damaging the clinical viability of TNX-103. LEVEL-2 is suspended or delayed, and the company is forced to pivot to earlier-stage pipeline assets (like TNX-201), resulting in a severe capital destruction and a drop to cash-value levels.

Base CaseCentral scenario

The Phase 3 LEVEL study meets its primary endpoint of change in 6-Minute Walk Distance (6MWD) at Week 12 with statistical significance and a clean safety profile. The global LEVEL-2 trial continues on track for enrollment completion by late 2027. The company utilizes its strong cash runway to prepare for NDA submission, driving substantial valuation expansion toward consensus targets.

Bull CaseUpside scenario

The bull case centers on TNX-103 (oral levosimendan) as a potential first-in-class therapy for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), a massive market with no currently approved treatments. The drug's safety profile is highly de-risked due to levosimendan's decades-long global clinical history in intravenous form. If the Phase 3 LEVEL and LEVEL-2 trials replicate the positive exercise improvements seen in Phase 2, TNX-103 could capture a substantial share of a multi-billion dollar addressable market, potentially leading to a lucrative buyout by big pharma.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-in-class therapeutic candidate (TNX-103) targeting PH-HFpEF, a major unmet medical need with zero FDA-approved treatments.
Imminent near-term catalyst with Phase 3 LEVEL study topline data expected in Q3 2026.
Strong balance sheet with $118.8 million in cash as of Q1 2026, securing operational runway through at least Q1 2028.
Strengthened leadership team with the appointments of a new CFO (Thomas Staab) and CCO (Timothy Healey) to prepare for commercialization.

Key Investment Risks

Binary clinical trial risk: Failure of the Phase 3 LEVEL study to meet its primary endpoint would severely impact the company's valuation.
Development and regulatory hurdles: Potential delays in the global LEVEL-2 trial enrollment or unexpected FDA requirements.
Pre-revenue status: The company has no commercialized products and will continue to generate net losses for the foreseeable future.

Thesis Invalidation Triggers

Failure of the Phase 3 LEVEL study to achieve statistical significance on the primary endpoint of 6MWD.
Unforeseen severe adverse safety signals in the LEVEL trial leading to a clinical hold.
Significant delays in LEVEL-2 trial site activation or patient recruitment pushing the enrollment timeline past 2027.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.